Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hannah Moll
Institution:
University of Zurich
Observed institutions:
University of Zurich,
University Children's Hospital Zurich
ORCID:
0000-0003-3765-9864
Observed ORCID:
0000-0003-3765-9864
OpenAlex ID:
A5065162195
GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study
2024
·
Hannah Moll
, Eliane Frey
, et al.
·
EClinicalMedicine
·
97
PDF
The Role of CD200–CD200 Receptor in Human Blood and Lymphatic Endothelial Cells in the Regulation of Skin Tissue Inflammation
2022
·
Dominic Rütsche
, Katarzyna Michalak-Micka
, et al.
·
Cells
·
16
PDF
Characteristics and expectations of people with multiple sclerosis using complementary therapies: A cross-sectional survey from the swiss multiple sclerosis registry
2025
·
Jesus Lopez-Alcalde
, Nina Steinemann
, et al.
·
Multiple Sclerosis and Related Disorders
·
7
Preferences for benefit and harm outcomes of GLP-1 receptor agonists in adults with overweight or obesity: a multinational best–worst scaling study
2025
·
Hannah Moll
, Milo A Puhan
, et al.
·
medRxiv
·
2
PDF
Corrigendum to “GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study” eClinicalMedicine 2024;73:102661
2026
·
Hannah Moll
, Eliane Frey
, et al.
·
EClinicalMedicine
Novel personalised patient decision aid on GLP-1 receptor agonists in obesity care: Design and development
2026
·
Hannah Moll
, Milo A. Puhan
, et al.
·
SSRN Electronic Journal
PDF
Show more works
View as search
Works count:
6
Citation count:
122
H-index:
3
I10-index:
2
Year
Topic
Type